ArticleDrug design, development and therapy2012
Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis.
Article in Drug design, development and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Sivelestat for septic patients with acute respiratory distress syndrome: a systematic review and meta-analysis of a deadly duo.Frontiers in medicine · 2025Pooled it
- Advances in anti-inflammatory treatment of sepsis-associated acute respiratory distress syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Neutrophil elastase inhibitor (Sivelestat) in the treatment of acute respiratory distress syndrome induced by COVID-19: a multicenter retrospective cohort study.Respiratory research · 2025Observational
- Effect of sivelestat sodium on the incidence of ventilator-associated pneumonia in patients with sepsis and ARDS.Frontiers in medicine · 2025Article
- A comparative analysis of sivelestat sodium hydrate and ulinastatin combination therapy in the treatment of sepsis with acute respiratory distress syndrome.BMC pulmonary medicine · 2024Article
- The beneficial effects of neutrophil elastase inhibitor on gastrointestinal dysfunction in sepsis.Clinical and translational science · 2024Article
- In vitro atomization analysis and evaluation of inhalable sodium sivelestat formulations.PloS one · 2024Article
- Article
- Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways.Biomolecules & biomedicine · 2023Article
- Efficacy and safety of sivelestat sodium for the treatment of inflammatory response in acute Stanford type A aortic dissection: a retrospective cohort study.Journal of thoracic disease · 2022Article
- Neutrophil elastase inhibition effectively rescued angiopoietin-1 decrease and inhibits glial scar after spinal cord injury.Acta neuropathologica communications · 2018Article
- Endogenous PGIProstaglandins & other lipid mediators · 2018Article
- Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions.Seminars in immunopathology · 2018Review
- Perioperative "remote" acute lung injury: recent update.Journal of biomedical research · 2017Article
- Nonmicrobial-mediated inflammatory airway diseases--an update.Journal of physiology and biochemistry · 2014Review
- Effect of a selective neutrophil elastase inhibitor on mortality and ventilator-free days in patients with increased extravascular lung water: a post hoc analysis of the PiCCO Pulmonary Edema Study.Journal of intensive care · 2014Article
- Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome.Therapeutics and clinical risk management · 2014Review
- Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis.Drug design, development and therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of sivelestat in the treatment of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) has not been established. In part, this is due to the wide variety of factors involved in the etiology of ALI/ARDS. In this study, we examined the efficacy of sivelestat in patients with ALI/ARDS associated with abdominal sepsis.
methodsThe subjects were 49 patients with ALI/ARDS after surgery for abdominal sepsis. The efficacy of sivelestat was retrospectively assessed in two treatment groups, ie, a sivelestat group (n = 34) and a non-sivelestat group (n = 15).
resultsThe sivelestat group showed significant improvements in oxygenation, thrombocytopenia, and multiple organ dysfunction score. The number of ventilator days (6.6 ± 6.1 versus 11.1 ± 8.4 days; P = 0.034) and length of stay in the intensive care unit (8.5 ± 6.2 versus 13.3 ± 9.5 days; P = 0.036) were significantly lower in the sivelestat group. The hospital mortality rate decreased by half in the sivelestat group, but was not significantly different between the two groups.
conclusionAdministration of sivelestat to patients with ALI/ARDS following surgery for abdominal sepsis resulted in early improvements of oxygenation and multiple organ dysfunction score, early ventilator weaning, and early discharge from the intensive care unit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.